BALCAO · RETAIL-RETAIL STORES, NEC · SMALL CAP
Regenerative Medical Technology Group Inc. RMTG
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.1M
▲ 24.2% vs FY2024
EPS · FY25
$-0.62
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-153.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.1M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 153 cents on every revenue dollar this year.
Per share
USD -0.62
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-17.0%
Net margin-153.2%
Return on assets-188.0%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+147.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+49.4%
+147.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+20.9%
Change, 10 years—
The share count grew 21% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.5M
total assets, end of FY2025
Total assetsUSD 4.5M
EquityUSD -34.7M
CashUSD 956,718.00
Gross debtUSD 21.1M
Net debtUSD 20.1M
Current ratio0.03×
Net debt stands at -58% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
0.0
−0.0
·
·
·
·
·
·
EBITDA $B
−0.0
0.0
−0.0
·
·
·
·
·
·
Income tax $B
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.62
−0.44
−0.79
−0.45
−1.12
−0.63
−0.47
−0.50
−0.11
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
36 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed